ARTICLE | Company News
Millennium, Xoma Ltd. deal
October 18, 2004 7:00 AM UTC
The companies restructured a 2001 deal to develop MLN2222 (CAB-2) recombinant fusion protein that blocks the activity of complement C3 convertase and C5 convertase to prevent complications of CABG sur...